Last reviewed · How we verify
NCT03913039
Reduction of Prostate Biopsy Morbidity
trial testing Transperineal biopsy Protocol in Prostate Cancer in 157 participants. Completed in 31 December 2021.
31 October 2021
Quick facts
| Lead sponsor | Maimonides Medical Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 157 |
| Start date | 1 May 2019 |
| Primary completion | 31 October 2021 |
| Estimated completion | 31 December 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Transperineal biopsy Protocol
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
Sponsor
Maimonides Medical Center
Who can join
Adults 18 to 120, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Prostate biopsy is typically performed via either the transrectal or transperineal approach. This study is a case-control study being done to determine if a novel prostate biopsy protocol incorporating a transperineal approach, rectal swab to detect resistant bacteria and broad antibiotic prophylaxis will reduce infectious complications and hospital readmission compared to current biopsy practices.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03913039
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other Maimonides Medical Center trials
Trials by the same sponsor.
- NCT07513493 — Pipelle vs the Curved Aspirator Device · Phase 4 · recruiting
- NCT07221175 — Operator Radiation Dose Using Ultra-Low Fluoroscopic Pulse Rate Versus Standard In Performing Coronary Angiography Via R · NA · withdrawn
- NCT06107725 — Maimonides Minocycline in Stroke Study · Phase 2, PHASE3 · terminated
- NCT06085586 — Fibulink Syndesmosis Repair System With Early Full-Weight Bearing · NA · recruiting
- NCT05615948 — Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03913039 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Maimonides Medical Center
- Last refreshed: 10 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03913039.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing